4,4'-Dihydroxychalcone

4,4'-Dihydroxychalcone

SCHEMBL773589

O=C(C=Cc1ccc(O)cc1)c1ccc(O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ F3 P13726 3/20 1.00
▸ MAPT P10636 6/20 0.82
▸ RAB9A P51151 4/20 0.82
▸ MAOB P27338 3/20 0.82
▸ MAOA P21397 2/20 0.82
▸ ESR1 P03372 1/20 0.82
▸ ESR2 Q92731 1/20 0.82
▸ CXCL12 P48061 1/20 0.82
▸ POLB P06746 1/20 0.82
▸ KMT2A Q03164 4/20 0.81
▸ MEN1 O00255 3/20 0.81
▸ CYP3A4 P08684 2/20 0.81
▸ HSPD1 P10809 2/20 0.81
▸ HSPE1 P61604 2/20 0.81
▸ CYP1B1 Q16678 2/20 0.81
▸ PKM P14618 1/20 0.81
▸ NFKB1 P19838 1/20 0.81
▸ NFKB2 Q00653 1/20 0.81
▸ RELA Q04206 1/20 0.81
▸ ALDH2 P05091 1/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25236411 1.00 F3 (1.00) F3MAPTRAB9AMAOBMAOA
4,4'-Dihydroxychalcone SCHEMBL773588 1.00 F3 (1.00) F3MAPTRAB9AMAOBMAOA
SCHEMBL10787169 1.00 F3 (1.00) F3MAPTRAB9AMAOBMAOA
SCHEMBL25211913 1.00 F3 (1.00) F3MAPTRAB9AMAOBMAOA
SCHEMBL10703657 1.00 F3 (1.00) F3MAPTRAB9AMAOBMAOA
SCHEMBL25223420 1.00 F3 (1.00) F3MAPTRAB9AMAOBMAOA
4,4'-Dihydroxychalcone SCHEMBL25202156 1.00 F3 (1.00) F3MAPTRAB9AMAOBMAOA
SCHEMBL25208810 0.92 F3 (0.85) F3MAPTRAB9AMAOBMAOA
SCHEMBL9100396 0.92 F3 (0.85) F3MAPTRAB9AMAOBMAOA
SCHEMBL10299734 0.92 F3 (0.85) F3MAPTRAB9AMAOBMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 397 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250326839-A1 TREATMENT OF DISEASES RELATED TO COLONY-STIMULATING FACTOR 1 RECEPTOR DYSFUNCTION USING TREM2 AGONISTS VIGIL NEUROSCIENCE INC (US) 2025-10-23 — — US claimed
US-20250282866-A1 TREATMENT OF DISEASES RELATED TO ATP-BINDING CASSETTE TRANSPORTER 1 DYSFUNCTION USING TREM2 AGONISTS VIGIL NEUROSCIENCE INC (US) 2025-09-11 — — US claimed
EP-4255567-A1 TREATMENT OF DISEASES RELATED TO ATP-BINDING CASSETTE TRANSPORTER 1 DYSFUNCTION USING TREM2 AGONISTS Vigil Neuroscience, Inc. (US) 2023-10-11 — — EP claimed
US-20230082623-A1 TREATMENT OF DISEASES RELATED TO ATP-BINDING CASSETTE TRANSPORTER 1 DYSFUNCTION USING TREM2 AGONISTS VIGIL NEUROSCIENCE, INC. 2023-03-16 — — US claimed
WO-2022120390-A1 TREATMENT OF DISEASES RELATED TO ATP-BINDING CASSETTE TRANSPORTER 1 DYSFUNCTION USING TREM2 AGONISTS VIGIL NEUROSCIENCE, INC. (US) 2022-06-09 — — WO claimed
US-9877946-B2 Method for treating, managing, inhibiting, or preventing obesity Research & Business Foundation Sungkyunkwan University (KR) 2018-01-30 — — US claimed
US-20170087126-A1 COMPOSITION FOR INDUCING DIFFERENTIATION INTO BEIGE AND BROWN ADIPOCYTES AND METHOD OF INDUCING THE SAME RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVER SITY (KR) 2017-03-30 — — US claimed
US-9549908-B2 Composition for inducing differentiation into beige and brown adipocytes and method of inducing the same Research & Business Foundation Sungkyunkwan University, Ltd. (KR) 2017-01-24 — — US claimed
US-20150374643-A1 COMPOSITION FOR INDUCING DIFFERENTIATION INTO BEIGE AND BROWN ADIPOCYTES AND METHOD OF INDUCING THE SAME Research & Business Foundation Sungkyunkwan University (KR) 2015-12-31 — — US claimed
US-20120070515-A1 Composition Comprising the Extract of Anemarrhena Asphodeloides Bunge or the Compounds Isolated from the Same for Preventing and Treating Lipid Metabolism Disorder EWHA UNIVERSITY- INDUSTRY COLLABORATION FOUNDATION (KR) 2012-03-22 — — US claimed
US-5342904-A Polymer modified adducts of epoxy resins and active hydrogen containing compounds containing mesogenic moieties THE DOW CHEMICAL COMPANY (US) 1994-08-30 — — US claimed
US-5248740-A Thioepoxides, liquid crystal polymers THE DOW CHEMICAL COMPANY (US) 1993-09-28 — — US claimed
US-5235008-A Curable THE DOW CHEMICAL COMPANY (US) 1993-08-10 — — US claimed
US-5182340-A Molding materials having shorter gel time with aliphatic amine curing agents THE DOW CHEMICAL COMPANY (US) 1993-01-26 — — US claimed
US-5164464-A Liquid crystalline polymers, acrylated epoxy resins THE DOW CHEMICAL COMPANY (US) 1992-11-17 — — US claimed
US-4962163-A ADVANCED POLYEPOXIDES AND EPOXY RESINS MODIFIED BY AN UNSATURATED CARBOXYLIC ACID; CURED COATING AND FILMS HAVINGI IMPROVED TENSILE AND FLEXURAL STRENGTH AND MODULUS THE DOW CHEMICAL COMPANY (US) 1990-10-09 — — US claimed
EP-0379058-A2 Vinyl ester resins containing mesogenic/rigid rodlike moieties THE DOW CHEMICAL COMPANY (US) 1990-07-25 — — EP claimed
US-4877711-A DURABLE PRINTING PLATES FUJI PHOTO FILM CO., LTD. (JP) 1989-10-31 — — US claimed
US-4863835-A UNSATURATED POLYESTER, BENZYL ALCOHOL, TETRAHYDROFURFURYL ALCOHOL, ACID MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) 1989-09-05 — — US claimed
US-4279930-A Process for treating inflammation THE UPJOHN COMPANY (US) 1981-07-21 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170087126-A1 COMPOSITION FOR INDUCING DIFFERENTIATION INTO BEIGE AND BROWN ADIPOCYTES AND METHOD OF INDUCING THE SAME FABP4, PLIN1, PRDM7 F3 3585/4885MAPT 1236/4885RAB9A 4514/4885
US-20150374643-A1 COMPOSITION FOR INDUCING DIFFERENTIATION INTO BEIGE AND BROWN ADIPOCYTES AND METHOD OF INDUCING THE SAME FABP4, PLIN1, PRDM7 F3 3585/4885MAPT 1236/4885RAB9A 4514/4885
US-20120070515-A1 Composition Comprising the Extract of Anemarrhena Asphodeloides Bunge or the Compounds Isolated from the Same for Preventing and Treating Lipid Metabolism Disorder FABP4, ACACB, LIPC F3 3182/4885MAPT 2597/4885RAB9A 2255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback